A Pilot Study Exploring the Effects of Circadian Phase on Influenza Vaccination Antibody Responses
Article information
Abstract
Objective
Conventional investigations into vaccination scheduling have relied on fixed clock time, which fails to account for individual circadian phase. This study investigated the feasibility of exploring the hypothesis that an individual’s circadian phase at the time of vaccination is related to antibody response rather than time of day alone.
Methods
Twenty healthy adults (aged 20–28) underwent continuous wrist actigraphy monitoring for 14 days using the Corsano Cardiowatch 287-2B. Participants were randomized to morning (08:00–09:00 am) or afternoon (4:00–5:00 pm) influenza vaccination times. Circadian profiles were constructed using cosinor modeling of biomarkers. Hemagglutination inhibition assays quantified H1N1 and H3N2 antibody titers at baseline and 30 days post-vaccination. Regression analyses evaluated associations between circadian phase at the time of vaccination and antibody response.
Results
Cortisol peak phase difference at time of vaccination had a positive association with antibody magnitude for both H1N1 and H3N2 strains (H1N1: R2=0.516, p=0.001; H3N2: R2=0.344, p= 0.012). Heart rate variability (HRV) trough phase difference at the time of vaccination had a negative association with antibody magnitude for H1N1 and H3N2 strains (H1N1: R2=0.636, p=0.001; H3N2: R2=0.616, p=0.001). No significant differences were found in antibody magnitude between morning and afternoon vaccination groups.
Conclusion
Circadian phase of cortisol and HRV, estimated using wrist actigraphy, may be associated with differences in antibody response to the influenza vaccine. These preliminary findings support further investigation into the relationship between individual circadian timing and adaptive immune function.
INTRODUCTION
Circadian rhythms orchestrate daily fluctuations in physiology and behavior [1]. These rhythms extend far beyond the basic sleep–wake cycle, exerting wide-ranging effects on metabolic, cardiovascular, and immune function that have been extensively studied in both animals and microorganisms [1]. At an environmental level, light is the primary input, exerting its influence as it interacts with photoreceptors in the retina [2]. At the central neural level, the suprachiasmatic nucleus receives input from the retinohypothalamic tract and is the master controller of a cascade of pathways [2]. At the cellular level, the clock is maintained by transcriptional–translational feedback loops involving core genes such as CLOCK and BMAL1, which activate the expression of PER and CRY [3]. These, in turn, inhibit their own transcription, creating sophisticated rhythmic oscillations with a 24-hour periodicity [2].
The immune system is particularly sensitive to circadian control. Murine models show that clock components regulate adaptive immune modulators, including cytokines, chemokines, and antigen receptors [3]. For example, BMAL1 influences monocyte trafficking and pro-inflammatory cytokine production, while CLOCK regulates NF-κB signaling pathways [3]. Toll-like receptor 9, which is critical for innate and adaptive immunity, also demonstrates circadian expression in mice, influencing vaccine responses [4]. This influence extends to B-cell and T-cell control, facilitating expression of key migratory regulators such as C-C chemokine receptor type 7, C-X-C motif chemokine receptor 4 (CXCR4), and interleukin-7 receptor (IL-7R) [5]. Expression of these proteins is of particular importance when considering priming and antibody generation, where leukocyte migration between the bloodstream and secondary lymphoid tissue is key.
Vaccine chronotherapy has recently emerged as an area of clinical interest. Several human studies have examined the timing of vaccination and have yielded mixed results [6,7]. Several studies have investigated the effect of temporal vaccination and demonstrate that morning vaccination can enhance antibody responses compared to afternoon administration [6]. However, results remain mixed; vaccine-dependent, and prior work has treated time of day as a fixed variable without accounting for interindividual variability in circadian rhythms [7]. It has been shown that environmental disruptions to clock phase synchrony (shift work, social jet lag, sleep restriction, and nocturnal light exposure) lead to negative health outcomes, including diabetes, cardiovascular disease, and immunosuppression [8]. Because circadian phase differs among individuals and can be drastically influenced by environmental factors, the same objective time may reflect different physiological states, suggesting circadian phase, rather than time-of-ay, may better predict vaccine efficacy [6-8].
When considering the importance of vaccination effectiveness, the influenza vaccine stands out as a prime candidate. Influenza is a vaccine-preventable disease that can cause symptoms such as fever, aches, chills, discomfort, and headache. While the majority of subjects recover from the disease, at-risk groups may develop severe complications, leading to 290,000–650,000 deaths each year [9]. Because influenza viruses undergo continuous genetic drift, they are constantly evolving. As a result, vaccines must be updated each year to better match the strains circulating in the population. In rapid succession, inactivated vaccines are produced from candidate vaccine viruses (CVVs) with the goal of providing subjects with active immunity in the form of antibodies targeting one of the major viral membrane glycoproteins: hemagglutinin [10]. Despite this specific targeting, even if CVVs are matched appropriately, vaccine effectiveness remains suboptimal.
Seasonal influenza vaccination from 2009–2025 demonstrated large variability, ranging from 19%–60% effectiveness, and was estimated as 40%–60% effective when the vaccine strains are antigenically well-matched [11]. This variance is historically defined as a reflection of several concepts: the match between the strain included in the vaccine and the circulating virus, and the subject’s history of previous vaccination or infection [10]. However, other potential factors to vaccine-mediated immune responses exist, and this feasibility study was designed to explore the hypothesis that individualized circadian rhythms impact the antibody response induced by this vaccine platform.
To investigate the correlation between individual circadian rhythms and immune responses against vaccines, this pilot study examined the possible role of circadian phase in humoral immune responses against influenza and identified potential avenues to further investigate this relationship. Several methods currently exist to evaluate circadian phase in humans. Endogenous melatonin, core body temperature (CBT), and cortisol have been widely used to infer circadian rhythm in humans [12]. However, these methods have historically been either invasive or subject to activity masking [13]. With the introduction of wrist actigraphy, an alternative method of continuous data collection has emerged, enabling non-invasive determination of one’s circadian rhythm in daily life. This pilot study utilized non-invasive wrist actigraphy monitoring in subjects using the Corsano Cardiowatch 287-2B, a wearable biosensor that continuously estimates rhythms of many biometric measurements, namely: cortisol, heart rate (HR), respiratory rate (RR), CBT, skin body temperature (SBT), and stress. The aim of this study was to determine the feasibility of using this data set to explore the hypothesis that antibody titers would differ based on an individual’s biometric phase at the time of vaccination. Using the biosensor data, we examined individual circadian phases and then compared influenza virus antibody titers in participants vaccinated at different points relative to their various rhythms.
METHODS
The study was reviewed and approved by the Institutional Review Board at Touro University Nevada (TUNIRB000314). Participants were required to provide informed consent before participating, and no identifiable personal data was collected.
Recruitment, participants
For the study, 20 healthy young students (10 male, 10 female, ages 20–28) were recruited from the student body of Touro University Nevada. Participants were asked to complete 3 surveys (informed consent, Morningness-Eveningness Questionnaire [MEQ] [14], and an intake form). Inclusion criteria included individuals who were graduate students at Touro University Nevada between the ages of 20 and 30 years old and who had not received an influenza vaccine within the past year.
Exclusion criteria included individuals with active hematological malignancy, individuals with an inherited immune deficiency, individuals with an infection of human immunodeficiency virus, individuals with bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigators, contraindicate a peripheral blood draw, individuals who have had a diagnosed influenza infection within the past 6 months, individuals who have already received an influenza vaccine or immunization of some kind within the past year, individuals who have an allergy to any component of the influenza vaccine, women who are pregnant, nursing, or planning a pregnancy, and individuals who are unable or unwilling to participate in all trial visits and assessments.
Using wrist actigraphy for data collection
This study utilized the Corsano Cardiowatch 287-2B (Corsano Health B.V.) as the sole device to monitor and collect physiologic data from participants. This bracelet is an FDA and Conformité Européenne–Medical Device Regulation-certified device. Participants were instructed on the use and care of the instrument before administration. This included charging, cleaning, and monitoring instructions via the Corsano smartphone application. At this point, participants were de-identified and given randomly generated patient identification codes, linking survey results, physiological data collected via bracelet, antibody titers, and erythrocyte sedimentation rate results. The bracelet continuously collected and uploaded encrypted data to the Corsano Cloud (General Data Protection Regulation and Health Insurance Portability and Accountability Act compliant).
The Corsano bracelet contains a plethora of sensors, including a galvanic skin response sensor, a triaxial accelerometer, a photoplethysmography module (containing 7 LEDs; Green, Red, and Infrared wavelengths; 2 photodiodes), a surface probe thermometer, and a heatflux sensor (greenteg). These sensors generated approximations of the following biometrics: pulse rate, SpO2, respiration rate, skin temperature, CBT, steps, energy expenditure, heart rate variability, stress, estimated cortisol contributions, and sleep data.
Data processing pipeline
Raw biometric data were processed and analyzed using custom code and available packages in R (v4.4.1; R Foundation for Statistical Computing), including CircaCompare [15] and GLMMcosinor [16]. Comma-separated values files containing raw biometric data were processed using a custom R pipeline and filtered to exclude physiologically impossible values as artifacts. The pipeline generated two primary outputs: Longitudinal Datasets and a Circadian Profile. Longitudinal Datasets maintained a continuous timeline for the 2-week monitoring period for day-to-day visualization and analysis. Circadian Profile used a representative day, accounting for all information from the 2-week monitoring period and folding the data into a standardized 24-hour day representative of their personalized circadian rhythm. Each biometric was run through GLMMCosinor to generate a cosinor wave using a fundamental period of 24 hours and a second harmonic of 12 hours. Using this cosinor wave, key parameters were extracted, namely, the midline estimating statistic of rhythm (mesor), amplitude, acrophase (peak), and bathyphase (trough).
Intake, interventions, and timeline
Participants completed an intake survey and the MEQ on day 1. Subjects (n=20) were then randomly assigned to either a morning vaccination group (8:00–9:00 am; n=10) or an afternoon vaccination group (4:00–5:00 pm; n=10). This intake survey collected demographic information, including age, sex, ethnicity, location, university affiliation, academic program, and upcoming high-stakes examinations. Medical history screening included prior autoimmune disease, recent or current illnesses, prescription or over-the-counter medication use, antibiotic use, and common chronic conditions such as asthma, allergies, diabetes, hypertension, and sleep disorders. Participants were also assessed for factors relevant to influenza vaccination safety, including history of respiratory illness, prior influenza infection, egg allergy, previous adverse vaccine reactions, and Guillain-Barré Syndrome. Lifestyle factors were recorded, including sleep habits, partner sleep status, exercise patterns, eating routines, and substance use within the past six months. Additional items included pregnancy status and recent exposure to significant life stressors or traumatic events. This intake form was used to verify eligibility, ensure vaccine safety, and characterize baseline participant health behaviors.
The MEQ is a 19-question survey used to assess individual daily rhythm patterns. The validated survey evaluates preferred sleep–wake timing, ease of awakening, alertness, and hunger in the morning, perceived peak performance times, and preferred scheduling of mentally or physically demanding tasks. Items also assess reliance on alarm clocks, likelihood of staying up late or waking early under unrestricted conditions, and self-identification as a “morning” or “evening” type. Scores from the MEQ were used to classify participants along the morningness-eveningness spectrum to characterize perceived chronotype.
Days 1–7, participants began continuous physiologic monitoring using the Corsano Cardiowatch. On day 8, a baseline blood sample was collected, followed by administration of the quadrivalent influenza vaccine. Monitoring with the Corsano Cardiowatch continued throughout days 9–16, during which participants also completed a wellness survey assessing interim symptoms and overall health.
The wellness survey confirmed that participants received the influenza vaccine and documented the date of administration. Participants reported post-vaccination symptoms, including fever, cough, fatigue, nausea, vomiting, other side effects, or no symptoms within the preceding seven days. Additionally, the survey asked whether participants sought medical care for these symptoms or required hospitalization.
No study-related interventions were required between days 17–35. On day 36, participants returned for the second intervention, which consisted of a follow-up blood sample to assess post-vaccination antibody responses.
Antibody quantification assays
Antibody titers were determined by hemagglutination (HA) inhibition assay using two influenza virus strains. Both H1N1 (BEI Resources, NIAID, NIH: influenza A virus, A/Connecticut/11/2023 [H1N1]pdm09 with NA-I223V and NA-S247N mutations, NR-59881) and H3N2 (BEI Resources, NIAID, NIH: influenza A virus, A/Baltimore/JH-335/2022 [H3N2], NR-59460) influenza strains were propagated in Madin-Darby canine kidney cells and tested in quantitative HA inhibition assays. Turkey red blood cells (RBC) (TURKEY RBCS 5%, Cat# 50-415-691, LAMPIRE Biological Laboratories) were prepared at 0.75% in 1x phosphate-buffered saline (PBS) and used in quantification assays. All sera were treated with cholera filtrate (Cat# C8772, Sigma-Aldrich), serving as a receptor-destroying enzyme (RDE) for nonspecific binders in sera.
Positive and negative controls were standardized and used in each Hemagglutination Inhibition Assay (HAI). A portion of all 19 participants’ post-vaccination sera was pooled, and aliquots were made for each assay. This undiluted serum then served as the positive control. Negative controls were standardized as PBS.
Direct HA assay
The HA assay was utilized to determine the volume of virus stock required. Specifically, it was used to generate HA units needed to agglutinate an equal volume of RBC solution and standardize the amount of virus used in each HAI. Target HA=4HA/25uL per WHO standard [17].
To prepare the plate, turkey RBCs were diluted to 0.75% in PBS. For H1N1, 25 μL of undiluted H1N1 antigen stock was added to the first wells of rows 1 and 2, followed by 50 μL of PBS to achieve a 1:2 dilution. The contents were then serially diluted across each row using 50 μL transfers to generate two-fold dilutions (1:2, 1:4, 1:8, etc.). After dilution, 50 μL was discarded from the last well in each row. The steps were repeated for H3N2 in rows 4 and 5. Then, 50 μL of the diluted RBC solution was added to all used wells to reach a total volume of 100 μL per well. The plate was incubated at room temperature for 30 minutes and then tilted at 90° for 25 seconds prior to reading the HA pattern.
HA was assessed following the incubation period by tilting the plate at 90° to distinguish agglutinated from non-agglutinated patterns. Non-agglutinated wells displayed a compact “button” or “halo” of RBCs that settled to the bottom, whereas agglutinated wells showed a diffuse, uniform reddish suspension without a defined button. The HA titer was defined as the highest virus dilution demonstrating complete hemagglutination. This dilution corresponds to 1 HA unit. To determine the volume containing 4 HA units for subsequent assays, two dilution steps preceding the endpoint were chosen for the hemagglutination inhibition assay (e.g., for an HA endpoint of 1:32, the 1:8 dilution would be chosen for the HAI assay).
HAI
RDE preparation was completed following the manufacturer’s instructions. The lyophilized cholera filtrate was reconstituted in 5.0 mL of sterile, deionized water (DI H2O). The resulting solution contained 0.01% as a preservative.
Serum aliquots (pre-vaccination and post-vaccination) were thawed on ice, and individual polymerase chain reaction (PCR) tube strips were prepared for each participant. For each participant, 10 μL of pre-vaccination serum was dispensed into four wells of a PCR strip, and 10 μL of post-vaccination serum was dispensed into the remaining four wells, yielding a total of twenty labeled strips. To generate a positive control, 10 μL from each post-vaccination sample was pooled into a 1-mL cuvette to obtain 200 μL, which was then allotted into four additional PCR tube strips (10 μL per well). In total, 24 PCR tube strips were prepared, each containing 10 μL of its designated serum. RDE was added to each tube (30 μL per reaction), briefly vortexed, and the samples were incubated at 37°C overnight to remove nonspecific inhibitors. The following day, samples were heat-inactivated at 56°C for 30 minutes to terminate RDE activity, then stored at 4°C for short-term use.
The working antigen solution was prepared based on the predetermined 4 HA-unit titer obtained from the HA. For twenty 96-well plates, each requiring 25 μL of antigen per well (2,400 μL per plate), a total volume of approximately 50 mL was prepared. Appropriate dilution calculations were performed to adjust the antigen stock to the final working concentration corresponding to 4 HA units.
A 0.75% RBC suspension was freshly prepared for use in the HAI assay. For twenty 96-well plates, each requiring 50 μL of RBC solution per well (4,800 μL per plate), a total volume of approximately 100 mL was prepared at the final working concentration.
A 1:2 serial dilution was performed beginning with an effective starting dilution of 1:8 (generated from a 1:4 serum–RDE mixture combined with 25 μL PBS). Each well of the 96-well plate was pre-filled with 25 μL PBS. Column 1 received 50 μL of the serum–RDE mixture, after which 25 μL was serially transferred across each successive well, discarding 25 μL from the final well. Subsequently, 25 μL of the 4-HA antigen solution was added to every well. Plates were tapped ten times on each side and incubated at room temperature for 30 minutes. Following the antigen-serum incubation, 50 μL of the 0.75% RBC suspension was added to all wells. The plates were then tapped ten times on all sides and incubated for an additional 30 minutes at room temperature.
HAI titers were recorded as the reciprocal of the last well demonstrating complete inhibition of HA (e.g., inhibition through a 1:32 dilution corresponds to a titer of 32). Plates were tilted at a 90° angle for 25 seconds to visualize RBC flow patterns. Complete inhibition appeared as a compact dot, partial inhibition as a dot with a partial streak, and no inhibition as a straight line extending to the bottom of the well.
RESULTS
Participants
A total of 20 individuals volunteered, met the inclusion criteria, consented, and were randomly assigned anonymous patient IDs. Of the 20 participants, 19 completed the full protocol and were included in the final per-protocol analysis. A single participant failed to complete the second blood draw at one month post-vaccination and was removed from the data pool.
Multi-system ambulatory circadian rhythm capture
Physiologic data captured via biometric wearables during the two-week monitoring period were processed through a custom analytical pipeline. Daily biological rhythms distinct from random activity noise were observed in all individuals for the measured variables: cortisol, breath, energy, stress, HR, heart rate variability (HRV), RR, CBT, and SBT. The custom analytical pipeline applied to the data collected generated representative rhythms for each individual (Figure 1).
Composite circadian model of HRV and cortisol rhythm. Light blue and light red represent weighted mean waveforms (plotted over 36 hours for visualization) of cortisol and HRV, respectively, with standard error of the mean ribbons. The dark red and dark blue lines represent the cosinor fit used to derive amplitude, mesor, and acrophase. Cortisol peak: 3:46 am, trough: 6:30 pm, HRV peak: 2:35 pm, HRV trough: 5:33 am. HRV, heart rate variability; rmssd, root mean square of successive differences.
Circadian biometric phase at vaccination predicts antibody response to both viral strains
We examined whether the phase of physiologic circadian rhythms at the time of vaccination was associated with differences in antibody titers against H1N1 and H3N2 after 1 month. Cortisol and HRV both showed significant differences in antibody response by vaccination phase. The following sections discuss trends in antibody magnitude for both viral strains, based on the peak/trough phase difference at the time of vaccination for cortisol and HRV. Negative phase differences indicate individuals vaccinated prior to their peak/trough, while positive phase differences indicate participants vaccinated after their peak/trough of the given rhythm.
Cortisol peak phase difference and antibody magnitude
Cortisol peak phase difference at the time of vaccination was significantly associated with antibody magnitude change one month post-vaccination. Phase data from participants (n=19) were compared to post-vaccination antibody magnitude difference for both viral strains. Linear (R2=0.516, p=0.001) and quadratic (p=0.011) models demonstrated a significant positive association, indicating that more positive peak phase differences at the time of vaccination were associated with increased titers to H1N1 (Figure 2). A similar result was observed for the H3N2 viral strain, where a linear regression (R2=0.344, p=0.012) (Figure 3) demonstrated a significant positive association.
Cortisol peak phase difference vs. magnitude of antibody response to H1N1 virus. Scatterplot with linear regression (green), quadratic regression (orange), and 95% confidence intervals (grey shading) demonstrating the relationship between cortisol peak phase difference at time of vaccination and magnitude change of H1N1 antibody titer after 1 month post-vaccination. The horizontal axis reflects the phase difference at the time of vaccination in hours; data points to the left of zero represent vaccination prior to peak cortisol phase, and data points to the right of zero represent vaccination post peak cortisol phase. Linear regression demonstrated a significant positive association (R2=0.516, p=0.001), indicating that vaccination after the peak cortisol phase has a higher magnitude change in H1N1 antibody titer 1 month post-vaccination. A quadratic model was also significant (p=0.011), suggesting potential nonlinearity in the phaseresponse relationship.
Cortisol peak phase difference vs. magnitude of antibody response to H3N2 virus. Scatterplot with linear regression (green) and 95% confidence intervals (grey shading) demonstrating the relationship between cortisol peak phase difference at time of vaccination and magnitude change of H3N2 antibody titer after 1 month post-vaccination. The horizontal axis reflects the phase difference at the time of vaccination in hours; data points to the left of zero represent vaccination prior to the peak cortisol phase, and data points to the right of zero represent vaccination post-peak cortisol phase. Linear regression demonstrated a significant positive association (R2= 0.344, p=0.012), indicating that vaccination after the peak cortisol phase has a higher magnitude change in H3N2 antibody titer 1 month post-vaccination.
HRV trough phase difference and antibody magnitude
HRV trough phase difference at the time of vaccination demonstrated a strong, consistent association with antibody response across both viral strains. Data from participants (n=19) were compared, where a linear regression (R2=0.636, p=0.001) for H1N1 titers and a quadratic model (p=0.006) demonstrated a significant negative association (Figure 4). For the H3N2 strain, linear (R2=0.616, p=0.001) and quadratic (p=0.009) models demonstrated a similar result and significant negative association (Figure 5).
HRV trough phase difference vs. magnitude of antibody response to H1N1 virus. Scatterplot with linear regression (green), quadratic regression (orange), and 95% confidence intervals (grey shading) demonstrating the relationship between HRV trough phase difference at time of vaccination and magnitude change of H1N1 antibody titer after 1 month post-vaccination. The horizontal axis reflects the phase difference at the time of vaccination in hours; data points to the left of zero represent vaccination prior to the trough HRV phase, and data points to the right of zero represent vaccination post trough HRV phase. Linear regression demonstrated a significant negative association (R2=0.636, p=0.001), indicating that vaccination prior to HRV trough phase has a higher H1N1 antibody titer change 1 month post-vaccination. A quadratic model was also significant (p=0.006), suggesting potential nonlinearity in the phaseresponse relationship. HRV, heart rate variability.
HRV trough phase difference vs. magnitude of antibody response to H3N2 virus. Scatterplot with linear regression (green), quadratic regression (orange), and 95% confidence intervals (grey shading) demonstrating the relationship between HRV trough phase difference at time of vaccination and magnitude change of H3N2 antibody titer after 1 month post-vaccination. The horizontal axis reflects the phase difference at the time of vaccination in hours; data points to the left of zero represent vaccination prior to the trough HRV phase, and data points to the right of zero represent vaccination post trough HRV phase. Linear regression demonstrated a significant negative association (R2=0.616, p=0.001), indicating that vaccination prior to HRV trough phase has a higher H3N2 antibody titer change 1 month post-vaccination. A quadratic model was also significant (p=0.009), suggesting potential nonlinearity in the phase-response relationship. HRV, heart rate variability.
Steps peak phase difference and antibody magnitude
Steps peak phase difference at the time of vaccination demonstrated a significant positive association with the magnitude of antibody response to one viral strain. Analysis of participant data (n=19) and linear regression (R2=0.251, p=0.036) indicated that vaccination during the post-steps peak phase is associated with higher H1N1 antibody titers one month post-vaccination (Figure 6). No significant association was found with the H3N2 viral strain.
Steps peak phase difference vs. magnitude of antibody response to H1N1 virus. Scatterplot with linear regression (green) and 95% confidence intervals (grey shading) demonstrating the relationship between steps peak phase difference at time of vaccination and magnitude change of H1N1 antibody titer after 1 month post-vaccination. The horizontal axis reflects the phase difference at the time of vaccination in hours; data points to the left of zero represent vaccination prior to the peak steps phase, and data points to the right of zero represent vaccination post-peak steps phase. Linear regression demonstrated a significant positive association (R2=0.251, p=0.036), indicating that vaccination post-peak steps phase has a higher H1N1 antibody titer change 1 month post-vaccination.
Additional physiologic markers show no significant association
Investigations into breath, CBT, energy, HR, RR, and stress yielded no significant correlations.
Time of day vaccination was not associated with antibody response
Morning (n=10) and after (n=9) vaccination groups were used for secondary analysis of clock time effect on antibody titers. There was no significant difference in raw antibody titers or magnitude of response between morning and afternoon vaccination groups for either viral strain.
Subjective chronotype was inversely associated with antibody magnitude
Secondary analysis of predicted chronotype demonstrated a significant inverse relationship with antibody titer for both viral strains. Results of the MEQ yielded 6 participants classified as morning chronotype and 13 participants classified as intermediate chronotype (neither morning or evening). Linear regression showed that MEQ score was significantly inversely associated with magnitude change in H1N1 antibody titer (R2=0.279, p=0.009), and H3N2 antibody titer (R2=0.312, p=0.004), indicating that more morning chronotypes were associated with lower antibody responses.
Post-vaccination survey results
Results from the one-week post-vaccination survey revealed that seven individuals reported symptoms post-vaccination. In the morning group, 6 individuals reported symptoms, including fatigue, headache, and muscle aches. In the after group, 3 individuals reported symptoms including headache and fatigue. No individuals from either group reported illness, needed antibiotics, or were hospitalized.
DISCUSSION
Circadian phase is associated with influenza vaccine-induced antibody response
We observed that within our analyzed pilot study subject population of 19 healthy adults, the physiologic circadian phase of cortisol and HRV at the time of vaccination was associated with antibody responses to influenza A H1N1 and influenza A H3N2 viral strains present in the 2024–2025 seasonal influenza vaccine. There was also a link detected between the peak steps phase and the influenza A H1N1 viral strain. Despite the lack of association found between breath, energy, stress, CBT, SBT, HR, and RR phase and antibody response, the cortisol and HRV associations are supported by recent studies and suggest the existence of mechanisms linking circadian phase and type two immune responses, lymphocyte migration, and antibody production [5,18-20].
Rhythmic endocrine and autonomic signaling as possible mediators
While glucocorticoids are often used as exogenous medications in clinical practice for their immunosuppressive effects, steroid hormones, specifically endogenous cortisol, have been shown to influence type two immunity and T-helper 2 cells differentiation during the active phase of living organisms [18]. Glucocorticoids have been shown to drive diurnal oscillations in leukocytes, including T-cell and B-cell function, through influencing the expression of proteins such as IL-7R and CXCR4. Ultimately, cortisol, under the control of the hypothalamic-pituitary-adrenal axis, demonstrates a robust circadian rhythm, peaking in the early active phase. Our analysis allowed us to visualize cosine cortisol rhythms, which reflected this established variation. Rhythmic signaling influences Th2 cell differentiation, allowing for optimal responsiveness to antigenic stimulation, enabling strong responses during times of likely exposure to antigens [5]. Cortisol’s early morning-induced upregulation of CXCR4 on B lymphocytes, however, promotes migration to bone marrow and lymphoid tissue, influencing germinal center dynamics and plasma cell development [19]. Because glucocorticoids influence Th2 polarization, B-cell trafficking, and germinal center reactions, variation in cortisol phase may alter the efficacy of early adaptive priming and immune response and ultimately affect the magnitude of antibody production post-vaccination. Peak cortisol phase differences in this pilot study revealed a possible phase-dependent association with antibody response for both influenza strains, with a positive visual trend (Figures 2 and 3), suggesting that a vaccine administered at more positive phase differences along an individual’s endogenous cortisol rhythm might influence antibody production one month later.
HRV reflects beat-to-beat variability in heart rate primarily mediated by vagal tone, with higher variability typically observed at rest [20]. Our analysis allowed us to visualize cosine HRV rhythms, which reflected this trend with peaks in the rest phase and troughs in the active phase of participants. HRV trough phase difference suggested a phase-dependent association with response to both influenza virus strains and a negative visual trend. When considering the role of the autonomic nervous system in adaptive immune responses, sympathetic control in the active phase of organisms has been shown to influence T-cell migration from lymphoid organs and increased differentiation [5]. Conversely, increased parasympathetic tone has been shown to lead to reduced migration of B-cells to red pulp venous sinuses in the spleen, where they become antibody-secreting cells [21]. When considered alongside our observed association with the cortisol phase, these findings support a potential model in which measurable neuroendocrine phase may shape early cellular interactions that influence antibody magnitude.
Clock time may be insufficient to predict immune response
Our secondary analysis failed to detect a significant difference in raw antibody titer or antibody magnitude between morning and afternoon vaccination groups. These findings suggest that clock time alone was not associated with variability in vaccine response in this pilot study. However, it is possible that a larger study would detect differences.
The potential impact of perceived chronotype
An unexpected finding of the study was the detection of an inverse association between perceived chronotype (MEQ) and antibody response. This observation suggests that lower MEQ scores corresponding to more evening chronotypes were associated with higher antibody titers for both viral strains. Since chronotype represents intrinsic circadian phase, this finding may be explained by evening chronotypes exhibiting generally delayed cortisol rhythms [22]. Alternatively, this finding may be influenced by other behavioral and environmental factors that influenced immune regulation.
Limitations and future directions
The associations observed between cortisol, HRV at the time of vaccination, and antibody response in this pilot study warrant further investigation into the hypothesis that circadian phase may influence vaccine-induced immune response. This pilot study suggests that vaccine efficacy may not depend as much on clock time as it does on alignment with an individual’s circadian phase of endogenous autonomic and endocrine rhythms, which can be measured noninvasively via wrist actigraphy. However, larger-scale explorations of vaccine timing based on personalized biometric phase and chronotype with more complex statistical analyses that correct for multiple comparisons will be required to provide statistically significant evidence of a novel approach to improving vaccine effectiveness. One of the limitations of the study was the low sample size. Due to the limited funding inherent to this pilot study, a formal a priori power analysis was not feasible. Consequently, the sample size was determined pragmatically based on the available resources and materials. We also acknowledge that, given the large number of physiological variables examined relative to the pilot study’s sample size, some observed associations may represent false-positive findings arising from exploratory analyses. In addition, the Corsano Cardiowatch, along with many noninvasive wrist actigraphy products, relies on surrogate markers to estimate cortisol, so a concomitant direct cortisol measurement would strengthen future studies.
An additional consideration is the potential limitations of the influenza vaccination model. Given that the seasonal influenza vaccine is offered annually and targets a virus that is widespread throughout the population, there may be external variables that modulated our results. Specifically, we did not account for whether an individual received prior immunization, how many times they have received the vaccine, or the degree of exposure to circulating viral strains. To address this potential limitation, alternative vaccination models for which we may control potential modulating factors should be considered. One potential method is employing controlled primary immunization with a novel antigen and serologically confirmed naivety at enrollment with a vaccine that subjects do not have previous exposure to, such as the inactivated rabies vaccine, or one of the recently FDA-approved respiratory syncytial virus vaccines.
Notes
The authors have no potential conflicts of interest to disclose.
Availability of Data and Material
The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
Author Contributions
Conceptualization: Payson Broome, Samuel Park, Karen Duus, Jutta Ward, Deborah Bell-Pedersen. Data curation: Payson Broome, Thrisha Reddy, Michael Desouza, Krystal Robinson, Karen Duus, Terry Else. Formal analysis: Payson Broome, Samuel Park. Methodology: Payson Broome, Karen Duus, Samuel Park. Supervision: Karen Duus. Writing—original draft: Payson Broome, Thrisha Reddy, Michael Desouza, Krystal Robinson. Writing—review & editing: all authors.
Funding Statement
None
Acknowledgments
We sincerely thank Walter Losure, Deborah Fuller, Shelly Howlett, and Moises Gomez for their invaluable contributions and support throughout this project. We would also like to thank all study participants for their important contributions.
